NBP

NovaBridge Biosciences (NBP) SWOT Analysis Analysis (2026)

Invetso Score: 3.8/10 — Weak · Last Updated: 2026-08-01

Strengths

A very high current and quick ratio of 8.1 indicates strong near-term liquidity versus peers, reducing refinancing pressure and supporting operating flexibility.

Debt-to-equity of 0.013 and net debt to EBITDA of 0.94 suggest a light balance-sheet burden versus leveraged peers, limiting financial risk.

Cash conversion cycle of 0 implies efficient working-capital management relative to peers, which can preserve liquidity even when profitability is weak.

Weaknesses

Return on invested capital of -94.8% signals severe value destruction versus peers, indicating the business is not yet converting capital into durable returns.

The absence of reported operating and gross margins limits evidence of operating leverage, while peers with positive margins likely have structurally better earnings quality.

Weak profitability combined with only modest leverage metrics suggests capital efficiency, not balance-sheet stress, is the core structural weakness versus peers.

Opportunities

If management converts strong liquidity into higher-return deployment, NBP could narrow the gap with peers that already earn acceptable returns on capital.

A low leverage profile provides room to fund growth or restructuring without immediate balance-sheet strain, unlike more indebted peers.

Working-capital efficiency can support incremental scale-up if demand improves, giving NBP more operating flexibility than peers with tighter liquidity.

Threats

Persistent negative ROIC raises the risk that peers with positive capital returns will compound faster and widen the structural performance gap.

If liquidity is used to fund low-return assets, NBP could remain trapped below peers that allocate capital more productively.

Limited margin disclosure and weak profitability increase the chance that competitive pressure from better-earning peers will keep returns depressed.

Overall Score

NBP’s balance-sheet liquidity is comparatively strong, but deeply negative capital returns and weak profitability leave its structural positioning below most peers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on NovaBridge Biosciences. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →